Evidence map›Paper›PMID 26468955›Full record

ArticlePloS one2015

A Novel Dual Expression Platform for High Throughput Functional Screening of Phage Libraries in Product like Format.

Xiaodong Xiao, Yan Chen, Sheila Mugabe, Changshou Gao, Christine Tkaczyk, Yariv Mazor, Peter Pavlik, Herren Wu, William Dall'Acqua, Partha Sarathi Chowdhury

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaodong XiaoDept. of Antibody Discovery and Protein Engineering, MedImmune, LLC., Gaithersburg, MD, 20878, United States of America.
Yan ChenDept. of Antibody Discovery and Protein Engineering, MedImmune, LLC., Gaithersburg, MD, 20878, United States of America.
Sheila MugabeDept. of Biopharmaceutical Development, MedImmune, LLC., Gaithersburg, MD, 20878, United States of America.
Changshou GaoDept. of Antibody Discovery and Protein Engineering, MedImmune, LLC., Gaithersburg, MD, 20878, United States of America.
Christine TkaczykDept. of Infectious Diseases, MedImmune, LLC., Gaithersburg, MD, 20878, United States of America.
Yariv MazorDept. of Antibody Discovery and Protein Engineering, MedImmune, LLC., Gaithersburg, MD, 20878, United States of America.
Peter PavlikDept. of Antibody Discovery and Protein Engineering, MedImmune, LLC., Gaithersburg, MD, 20878, United States of America.
Herren WuDept. of Antibody Discovery and Protein Engineering, MedImmune, LLC., Gaithersburg, MD, 20878, United States of America.
William Dall'AcquaDept. of Antibody Discovery and Protein Engineering, MedImmune, LLC., Gaithersburg, MD, 20878, United States of America.
Partha Sarathi ChowdhuryDept. of Antibody Discovery and Protein Engineering, MedImmune, LLC., Gaithersburg, MD, 20878, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High throughput screenings of single chain Fv (scFv) antibody phage display libraries are currently done as soluble scFvs produced in E.coli. Due to endotoxin contaminations from bacterial cells these preparations cannot be reliably used in mammalian cell based assays. The monovalent nature and lack of Fc in soluble scFvs prevent functional assays that are dependent on target cross linking and/or Fc functions. A convenient approach is to convert scFvs into scFv.Fc fusion proteins and express them in mammalian cell lines for screening. This approach is low throughput and is only taken after primary screening of monovalent scFvs that are expressed in bacteria. There is no platform at present that combines the benefits of both bacterial and mammalian expression system for screening phage library output. We have, therefore, developed a novel dual expression vector, called pSplice, which can be used to express scFv.Fc fusion proteins both in E.coli and mammalian cell lines. The hallmark of the vector is an engineered intron which houses the bacterial promoter and signal peptide for expression and secretion of scFv.Fc in E.coli. When the vector is transfected into a mammalian cell line, the intron is efficiently spliced out resulting in a functional operon for expression and secretion of the scFv.Fc fusion protein into the culture medium. By applying basic knowledge of mammalian introns and splisosome, we designed this vector to enable screening of phage libraries in a product like format. Like IgG, the scFv.Fc fusion protein is bi-valent for the antigen and possesses Fc effector functions. Expression in E.coli maintains the speed of the bacterial expression platform and is used to triage clones based on binding and other assays that are not sensitive to endotoxin. Triaged clones are then expressed in a mammalian cell line without the need for any additional cloning steps. Conditioned media from the mammalian cell line containing the fusion proteins are then used for different types of cell based assays. Thus this system retains the speed of the current screening system for phage libraries and adds additional functionality to it.

Indexed as

Peptide LibraryAnimalsBacteriophagesCHO CellsCloning, MolecularCricetinaeCricetulusHEK293 CellsHigh-Throughput Screening AssaysHL-60 CellsHumansImmunoglobulin Fc FragmentsSingle-Chain AntibodiesImmunoglobulin Fc FragmentsPeptide LibrarySingle-Chain Antibodies

Identifiers

PMID26468955
PMCPMC4607404
OpenAlexW2291300445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.